Plain-English translation of NCT07546383 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a combination of two antibody medications called in patients with head and neck squamous cell carcinoma that has come back or spread after previous treatment. You would receive the medication every 3 weeks, and your doctor may also recommend chemotherapy alongside it based on your specific cancer characteristics and preferences. Researchers want to see how well this treatment works and how safe it is.
Head and neck cancer that returns or spreads after initial treatment is very difficult to treat, and patients need better options. This medication aims to boost your immune system's ability to fight the cancer cells by blocking proteins that normally hide tumors from your body's defense system.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic every 3 weeks to receive the antibody medications by infusion. If your doctor recommends it, you would also receive chemotherapy for up to 6 cycles during this time. The study includes a short initial safety phase with a few patients to make sure the treatment is tolerable. Researchers will monitor you with blood tests and scans to see how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China